Short-acting β2-agonist exposure and severe asthma exacerbations: SABINA findings from Europe and North America

Autor: Jennifer K. Quint, Sofie Arnetorp, Janwillem W.H. Kocks, Maciej Kupczyk, Javier Nuevo, Vicente Plaza, Claudia Cabrera, Chantal Raherison-Semjen, Brandie Walker, Erika Penz, Ileen Gilbert, Njira Lucia Lugogo, Ralf J.P. van der Valk, Andrew Fong, Christina Qian, Caroline Fabry-Vendrand, Chantal Touboul, Dorota Brzostek, Ekaterina Maslova, Filip Surmont, Helena Goike, Hitesh Gandhi, J.C. Korevaar, Joseph Tkacz, Karissa Johnston, Keith Peres da Costa, L. van Dijk, M. Vervloet, Michael Pollack, Paul Hernandez, Silvia Boarino, Stephen G. Noorduyn, Wendy Beekman-Hendricks, Y.M. Weesie

Publikováno v: 2309.10
Journal of Allergy and Clinical Immunology: In Practice, 10(9), 2297-2309.e10. American Academy of Allergy, Asthma and Immunology

Background: Expert national/global asthma management recommendations raise the issue whether a safe threshold of short-acting beta-2 agonist (SABA) use without concomitant inhaled corticosteroids (ICS) exists.Objective: To examine SABA and maintenanc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2f85f1f2dce410f743f44fb620b616c
http://hdl.handle.net/10044/1/96149